ALNY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.5B
+12.9%
1.3B
+10.6%
1.2B
+6.4%
1.1B
-12.2%
1.2B
Cost of Revenue
361.8M
+21.3%
298.3M
+43.7%
207.5M
-22.5%
267.7M
+35.7%
197.2M
Gross Profit
1.1B
+10.4%
992.7M
+3.4%
959.7M
+15.7%
829.3M
-21.2%
1.1B
Operating Expenses
750.5M
-1.4%
761.2M
+10.2%
691.0M
-0.9%
697.6M
+2.0%
683.8M
R&D
408.5M
-1.1%
413.1M
+13.2%
364.9M
-2.0%
372.2M
+3.7%
358.8M
SG&A
342.0M
-1.7%
347.9M
+7.9%
322.6M
-0.9%
325.4M
+1.0%
322.1M
Operating Income
345.8M
+49.4%
231.4M
-13.8%
268.6M
+103.9%
131.7M
-64.2%
368.0M
EBITDA
360.3M
+46.8%
245.3M
-13.1%
282.2M
+94.3%
145.2M
-62.0%
381.8M
Net Income
2.2B
+1217.6%
164.5M
-20.1%
206.0M
+10.5%
186.4M
-36.3%
292.7M
EPS (Basic)
$16.19
+1216.3%
$1.23
-20.6%
$1.55
+9.9%
$1.41
-36.8%
$2.23
EPS (Diluted)
$15.72
+1199.2%
$1.21
-19.9%
$1.51
+14.4%
$1.32
-38.3%
$2.14
Shares (Diluted)
138.0M
-0.2%
138.3M
+0.0%
138.2M
-2.0%
141.1M
+2.7%
137.3M
Alnylam Pharmaceuticals (ALNY) — Financials